List of Excipients in Branded Drug NICOTINE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Walgreens Company	NICOTINE	nicotine	0363-0455	METHACRYLIC ACID
Rugby Laboratories	NICOTINE	nicotine	0536-1108	METHACRYLIC ACID
Target Corporation	NICOTINE	nicotine	11673-194	ETHYLENE-VINYL ACETATE COPOLYMER

Generic Drugs Containing NICOTINE

Company	Ingredient	NDC	Excipient
Walgreen Company	nicotine polacrilex	0363-0124	ACESULFAME POTASSIUM
Walgreen Company	nicotine polacrilex	0363-0124	MAGNESIUM STEARATE
Walgreen Company	nicotine polacrilex	0363-0124	MANNITOL

What are the Most Frequently-Used Excipients in NICOTINE?

# Of NDCs	Excipient
54	ACACIA
195	ACESULFAME POTASSIUM
1	ACID YELLOW 3

Nicotine Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 28, 2026

Nicotine remains commercially attractive because the active ingredient is inexpensive, widely understood, and compatible with multiple delivery systems. The strongest opportunities are in excipient-enabled delivery: faster buccal absorption, longer residence time, improved taste, reduced irritation, dose consistency, and lower nitrosamine risk.

The commercial and regulatory pathway depends on the product category:

Product type	Primary U.S. pathway	Main commercial barrier	Excipient opportunity
Nicotine gum, lozenge, patch	FDA drug pathway, including OTC monograph products	FDA drug compliance and established competitors	Taste masking, release control, skin adhesion, irritation reduction
Nicotine oral pouch	Tobacco product pathway unless separately approved as a drug	Premarket tobacco application and youth-use scrutiny	pH control, moisture management, flavor, pouch fiber, dose uniformity
Nicotine inhaler or spray	FDA drug approval	Device-drug combination development	Aerosolization, plume control, mucosal tolerability
Nicotine e-liquid	Tobacco product pathway	PMTA, toxicology, manufacturing controls	Solvent selection, thermal degradation, flavor safety
Buccal or sublingual film	FDA drug pathway	Clinical bridging and formulation performance	Mucoadhesion, rapid dissolution, taste masking
Prescription cessation product	FDA NDA or applicable drug pathway	Clinical evidence and reimbursement	Controlled release, adherence, abuse-deterrent design

What excipients are most valuable in nicotine products?

The highest-value excipient functions are pH control, taste masking, mucosal residence, nicotine release control, moisture management, and protection against degradation.

Nicotine is a weak base with substantial volatility and an unpleasant taste. Its absorption changes materially with pH because the un-ionized form crosses biological membranes more readily. Formulators therefore use acids, bases, and buffers to balance absorption with irritation and palatability.

Core excipient functions

Function	Common excipient classes	Commercial purpose
pH adjustment	Carbonates, bicarbonates, phosphates, citrates, hydroxides	Increase or moderate free nicotine and control absorption
Nicotine salt formation	Benzoic, lactic, levulinic, malic, citric, or related acids	Improve handling, reduce volatility, alter sensory profile
Humectancy	Glycerol, propylene glycol, polyethylene glycol	Maintain moisture and control product feel
Binding and matrix formation	Cellulose derivatives, povidone, starches, gums	Build gum, lozenge, film, or pouch structure
Mucoadhesion	Carbomers, polycarbophil, alginate, cellulose polymers	Extend contact with oral mucosa
Taste masking	Sweeteners, flavors, ion-exchange resins, cyclodextrins, lipid systems	Reduce bitterness and throat irritation
Release control	Hydrophilic polymers, waxes, lipids, coated particles	Extend or delay nicotine delivery
Antioxidant protection	Tocopherols, ascorbate systems, sulfite alternatives where permitted	Reduce oxidation and color change
Aerosol control	Propylene glycol, glycerol, ethanol, surfactants	Control droplet size, vaporization, and plume
Skin delivery	Adhesives, permeation modifiers, backing films, release liners	Maintain patch adhesion and transdermal flux

An excipient is commercially valuable only when it improves a measurable product attribute. A new sweetener alone rarely creates durable differentiation. A formulation that produces a defined pharmacokinetic profile, reduces irritation, or improves stability has stronger regulatory and patent value.

How does nicotine salt selection affect product performance?

Nicotine salts can reduce free-base volatility and modify the sensory profile, but the acid, molar ratio, water content, and final pH determine product behavior.

In oral pouches and e-liquids, acids such as benzoic, lactic, and levulinic acid are used to form nicotine salts or partially neutralized systems. Lower pH generally reduces the fraction of un-ionized nicotine, which can reduce harshness but may also slow buccal absorption. Higher pH tends to increase free nicotine and accelerate absorption, while increasing irritation and sensory intensity.

A commercially useful salt system should be assessed across:

1. Nicotine content and delivered dose.
2. Free nicotine fraction.
3. pH and buffer capacity.
4. Moisture activity.
5. Nicotine migration during storage.
6. Color and odor stability.
7. Nitrosamine formation potential.
8. Oral or inhalation tolerability.
9. Manufacturing reproducibility.
10. Compatibility with packaging.

A patent claim directed only to a known nicotine salt may face prior-art pressure. Stronger protection generally combines the salt with a defined pH range, moisture range, delivery profile, pouch or device architecture, and measured pharmacokinetic result.

What formulations are protected by nicotine patents?

Nicotine patent protection is concentrated in delivery systems rather than in the active molecule. The core nicotine molecule and many conventional nicotine salt concepts are old. Current or recent patent activity has focused on:

• Buccal and sublingual films.
• Nicotine pouches with defined moisture and pH ranges.
• Controlled-release gum and lozenges.
• Metered-dose inhalers and vapor devices.
• Transdermal patches with specific adhesive and reservoir systems.
• Nicotine formulations with reduced irritation.
• Taste-masked nicotine particles.
• Nicotine compositions with selected acids or buffering systems.
• Device and cartridge designs.
• Manufacturing methods that improve dose uniformity.
• Packaging systems that limit moisture and nicotine loss.

Patent strength by claim type

Claim type	Typical strength	Main vulnerability
Nicotine molecule	Very low	Expired or unavailable composition-of-matter protection
Generic nicotine salt	Low to moderate	Extensive prior art and predictable salt screening
Specific salt plus pH and delivery profile	Moderate	Enablement and obviousness challenges
Buccal film composition	Moderate to strong	Design-around through polymer or process changes
Oral pouch with defined nicotine migration and moisture	Moderate	Prior art from tobacco pouch technology
Device plus formulation combination	Stronger	Narrow claim scope and device-specific infringement
Manufacturing process	Moderate	Difficult detection of process infringement
Pharmacokinetic performance claim	Potentially strong	Proof of infringement and written-description issues

Patent due diligence must separate active patents, expired patents, abandoned applications, pending continuations, and patents that were never listed in an FDA product database. Patent families should be reviewed by jurisdiction rather than counted by publication number.

What is the Orange Book status of nicotine products?

The Orange Book is relevant to approved nicotine drug products, but it does not provide a complete record of the U.S. nicotine market.

FDA-approved nicotine replacement products include drug-device combinations and prescription or nonprescription products approved through traditional drug pathways. Many OTC nicotine gum, lozenge, and patch products are marketed under the FDA OTC monograph framework or through approved applications. Tobacco-derived nicotine pouches and e-liquids are generally regulated as tobacco products, not as FDA-approved drugs.

The practical distinction is significant:

• An approved drug may have Orange Book-listed patents and exclusivity.
• An OTC monograph product usually competes through monograph compliance, branding, manufacturing, and distribution rather than a conventional innovator-generic structure.
• A nicotine pouch or e-liquid typically requires tobacco-product authorization rather than an ANDA pathway.
• A tobacco authorization does not create Orange Book listing rights.
• FDA tobacco authorization does not establish that a product is safe or approved as a cessation medicine. FDA describes authorization as a market-access decision under the tobacco statute, not a finding that the product is risk-free. [1]

A product-by-product Orange Book review is required for patent listing, therapeutic equivalence, and Paragraph IV analysis.

When does nicotine lose exclusivity?

Nicotine itself has no meaningful remaining composition-of-matter exclusivity. Exclusivity risk instead depends on the individual dosage form, approved application, patent family, and regulatory pathway.

Exclusivity timeline by product category

Product category	Exclusivity profile
Conventional nicotine gum	Primarily OTC monograph and formulation competition
Nicotine patch	Product-specific patents, adhesive claims, and brand protection
Nicotine lozenge	Formulation, taste, dissolution, and manufacturing claims
Prescription inhaler	NDA exclusivity and device-related patents
Nicotine spray	NDA or monograph issues, device and formulation claims
Nicotine pouch	Tobacco-product authorization and patent rights outside the Orange Book
E-liquid	PMTA authorization, trade secrets, and device/formulation patents
Buccal film	Potential NDA exclusivity, formulation patents, and method-of-use claims

Patent expiration must be calculated at the family level. The relevant date may differ because of terminal disclaimers, patent-term adjustment, patent-term extension, PTA, PTE, continuations, and foreign filing history. A patent publication date is not an expiration date.

Are Paragraph IV challenges relevant to nicotine products?

Paragraph IV challenges are relevant when a nicotine product is linked to an approved reference drug and has patents listed in the Orange Book. They are less relevant to nicotine products regulated under the tobacco pathway or to conventional OTC monograph products.

For a drug-device nicotine product, a potential ANDA applicant would assess:

• Whether the reference product has listed patents.
• Whether the proposed product can qualify as therapeutically equivalent.
• Whether the device is sufficiently similar.
• Whether the applicant can certify noninfringement or invalidity.
• Whether the reference product has remaining exclusivity.
• Whether the formulation falls within the listed claims.

A Paragraph IV case can produce a 30-month stay of approval under applicable Hatch-Waxman procedures if statutory conditions are met. The result depends on the listed patent, notice timing, lawsuit timing, and FDA’s regulatory position. [2]

For nicotine pouches, vapes, and other tobacco products, the principal risk is not Paragraph IV litigation. The commercial risks are PMTA denial or delay, enforcement against unauthorized products, patent litigation, trademark disputes, and manufacturing noncompliance.

What manufacturing and IP barriers affect nicotine excipient opportunities?

Manufacturing control is a major source of defensible value. Nicotine products can experience dose variability from volatility, migration, moisture exchange, pH drift, and incomplete mixing.

Key manufacturing barriers

Oral products

Gum, lozenges, films, and pouches require control of:

• Nicotine assay and content uniformity.
• Moisture activity.
• pH and buffer capacity.
• Nicotine migration into packaging.
• Excipient compatibility.
• Dissolution or release rate.
• Flavor loss.
• Microbial quality.
• Residual solvents.

For pouches, the pouch material, fiber density, fill weight, moisture, and seal integrity affect release. A formulation patent may be difficult to enforce if competitors use a different pouch substrate or adjust pH outside the claim range.

Inhaled products

Inhalation products require tight controls on:

• Aerosol droplet or particle size.
• Delivered dose uniformity.
• Vaporization temperature.
• Thermal decomposition.
• Device resistance.
• Leakage.
• Excipient degradation.
• Carbonyl and other toxicant formation.

Propylene glycol and glycerol are common aerosol carriers, but thermal degradation and flavor chemistry require toxicological review. Formulation changes that improve aerosol performance can create new impurities.

Transdermal products

Patches require control of:

• Adhesion over the labeled wear period.
• Nicotine flux.
• Reservoir stability.
• Skin irritation and sensitization.
• Backing and liner compatibility.
• Residual drug in the used patch.

A transdermal product with a new adhesive or release-control layer may have stronger patent differentiation than a patch that merely changes nicotine loading.

How can excipient strategy reduce nicotine regulatory risk?

Excipient selection should begin with the target pathway. The same ingredient can face different regulatory treatment in a drug, tobacco product, cosmetic, or consumer product.

For drug products, FDA considers the intended route, dose, exposure, and prior use. Inclusion in FDA’s Inactive Ingredient Database can support development, but database precedent does not automatically establish suitability for a new route, dose, or population. [3]

For tobacco products, manufacturers must address harmful and potentially harmful constituents, product chemistry, manufacturing controls, and population-level effects in the PMTA. The FDA tobacco framework requires evidence addressing the effect of the product on the health of the population as a whole. [4]

A lower-risk excipient program should:

1. Use pharmacopeial-grade materials where practical.
2. Avoid unnecessary novel excipients.
3. Screen for nitrosamine formation and contamination.
4. Control elemental impurities and residual solvents.
5. Evaluate flavor chemicals under the intended exposure route.
6. Establish extractables and leachables controls.
7. Link excipient specifications to critical quality attributes.
8. Generate stability data under accelerated and long-term conditions.
9. Assess pediatric exposure and accidental ingestion.
10. Preserve alternative formulations for design-around and supply continuity.

Nitrosamine control is particularly important because nicotine products may contain tobacco-derived impurities, nitrate or nitrite sources, amines, and moisture conditions that promote formation. FDA has issued guidance on nitrosamine risk management for drugs, and tobacco products face separate chemical and toxicological scrutiny. [5]

Which companies are challenging the nicotine market?

Competition is segmented by pathway and delivery format.

Major commercial groups

Segment	Representative companies or brands	Competitive basis
Nicotine gum and lozenges	Haleon, Perrigo, Dr. Reddy’s, regional OTC manufacturers	Brand, retail distribution, flavor, price
Nicotine patches	Haleon, Perrigo, Kenvue legacy assets, private-label manufacturers	Adhesion, wear time, price, pharmacy access
Oral nicotine pouches	Philip Morris International, British American Tobacco, Swedish Match, Imperial Brands, independent brands	Flavor, strength range, moisture, pouch comfort
E-cigarettes and vapor products	Altria, British American Tobacco, Japan Tobacco, Imperial Brands, independent manufacturers	Device performance, flavor, authorization, distribution
Prescription cessation products	Companies with approved inhaled or spray products	FDA approval, clinical evidence, pharmacy channel
Ingredient and excipient suppliers	BASF, Ashland, Roquette, Dupont legacy excipient businesses, specialty polymer suppliers	Polymer functionality, supply reliability, regulatory documentation

Corporate ownership changes frequently, particularly in nicotine and tobacco markets. Brand ownership, legal manufacturer, authorization holder, and excipient supplier should be verified separately in transaction and freedom-to-operate work.

What licensing deals are available in nicotine excipients and delivery?

Licensing opportunities are strongest where an excipient platform solves a specific product problem and can be transferred across nicotine formats.

Attractive licensing assets

• Mucoadhesive films with rapid dissolution.
• Taste-masking systems that preserve nicotine release.
• Low-moisture pouch systems with stable dose delivery.
• Controlled-release nicotine particles.
• Nicotine formulations with reduced throat irritation.
• Packaging systems that reduce nicotine loss.
• Inhalation excipients that improve plume consistency.
• Process analytics for nicotine content uniformity.
• Low-nitrosamine nicotine raw-material systems.
• Skin adhesives that maintain patch performance with lower irritation.

Commercial terms will depend on whether the asset is a formulation patent, a manufacturing trade secret, a regulatory package, or a combination. A patent alone has limited value if the formulation cannot meet stability, sensory, toxicology, and scale-up requirements.

How strong is the nicotine patent estate?

The nicotine patent estate is fragmented and format-specific. Core nicotine patents provide little protection. The stronger assets are narrow patents covering a formulation, delivery device, process, or combination of measurable product parameters.

A practical strength assessment should score each family on:

Criterion	High-value indicator
Claim scope	Covers formulation and delivery architecture
Remaining term	Meaningful term after prosecution and PTA
Enforceability	Product attributes are observable or discoverable
Regulatory linkage	Patent corresponds to an approved drug product
Design-around difficulty	Alternative excipient systems are not straightforward
Commercial relevance	Claim covers a high-volume product format
Geographic reach	United States, Europe, Canada, Australia, and key Asian markets
Supply dependence	Claim relies on difficult-to-replace excipient or process

Trade secrets may matter more than patents for mixing order, moisture control, coating conditions, and packaging parameters. Those assets are difficult to detect and can remain valuable after patent expiration, provided manufacturing confidentiality is maintained.

What generic launch risks exist for nicotine products?

Generic or private-label entry is most plausible for conventional gum, lozenges, and patches. Barriers are higher for approved inhalers, sprays, buccal films, and device-linked products.

Generic launch scenarios

Scenario	Likely timing pressure	Principal risk
OTC gum or lozenge	Rapid once compliant supply is available	Retail access and price erosion
Patch	Moderate	Adhesive performance, bioequivalence, brand loyalty
Approved inhaler	Slower	Device equivalence and patents
Buccal film	Moderate to slow	Clinical bridging and formulation claims
Nicotine pouch	Authorization-dependent	PMTA, youth-use controls, patent and trademark disputes
E-liquid	Highly constrained	PMTA authorization and chemical compliance

Revenue exposure is highest for products with broad pharmacy and mass-retail distribution. Excipient innovation can defend margins only when it produces a measurable consumer or regulatory advantage, such as fewer mouth lesions, improved flavor duration, faster onset, lower residue, or better adherence.

How does nicotine compare with other cessation drugs?

Nicotine has a lower active-ingredient cost and broader formulation flexibility than varenicline or bupropion. Its commercial disadvantage is intense competition and limited differentiation in conventional dosage forms.

Attribute	Nicotine	Varenicline	Bupropion
Main delivery formats	Oral, transdermal, inhaled, buccal, tobacco products	Oral tablet	Oral tablet
Excipient-led differentiation	High	Moderate	Moderate
OTC availability	Extensive for NRT	Generally prescription	Prescription and selected indications
Device dependence	Common in inhaled products	Low	Low
Patent concentration	Delivery systems and devices	Molecule and formulations	Molecule and formulations
Regulatory complexity	Split between drug and tobacco pathways	Drug pathway	Drug pathway
Consumer switching	High	Moderate	Moderate

Nicotine offers more opportunities for formulation licensing, but it also has greater pathway complexity and public-health scrutiny.

Key Takeaways

• Nicotine’s active molecule has little practical remaining exclusivity; commercial value is concentrated in delivery systems.
• The most attractive excipient opportunities are pH control, taste masking, mucoadhesion, moisture management, controlled release, and low-nitrosamine design.
• Oral pouches, buccal films, inhalers, and transdermal systems offer more formulation differentiation than conventional gum.
• Orange Book and Paragraph IV analysis applies mainly to approved nicotine drug products, not to most nicotine pouches or e-liquids.
• Patent strength depends on defined formulation parameters, delivery performance, manufacturing steps, and enforceability.
• Regulatory strategy must distinguish FDA drug approval from tobacco-product authorization.
• Manufacturing know-how can be more valuable than a narrow formulation patent.
• The best licensing assets improve a measurable attribute and transfer across multiple nicotine products.

FAQs

Are nicotine pouches protected by drug patents?

Most nicotine pouches are regulated as tobacco products rather than approved drugs. Their protection generally comes from formulation patents, pouch construction patents, trademarks, trade secrets, and regulatory authorization. Orange Book listing is usually not the primary protection mechanism.

Which excipients improve nicotine pouch absorption?

pH modifiers and buffers that increase the un-ionized nicotine fraction can improve buccal absorption. Humectants, pouch fibers, and mucoadhesive polymers affect moisture, residence time, and release. Higher absorption can also increase irritation, so performance must be balanced against tolerability.

Can a new nicotine salt support a patent?

A salt alone may face substantial prior art. A stronger patent position may arise from a defined salt, pH range, moisture range, delivery profile, stability result, or combination with a specific pouch, film, inhaler, or transdermal system.

Are nicotine flavors patentable?

Flavor identity alone is often weak protection. A formulation combining flavor, nicotine salt, pH, release characteristics, sensory performance, and stability may provide stronger patent value. Trade-secret protection may also apply to flavor ratios and processing conditions.

What is the largest unmet excipient opportunity in nicotine?

The strongest broad opportunity is a stable, low-irritation oral delivery platform that provides consistent nicotine exposure, masks bitterness, limits nicotine migration, reduces nitrosamine risk, and can be manufactured at high throughput.

References

1. U.S. Food and Drug Administration. (n.d.). Tobacco products: Marketing tobacco products in the United States. https://www.fda.gov/tobacco-products
2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application abbreviated approval process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. U.S. Food and Drug Administration. (n.d.). Premarket tobacco product applications. https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/premarket-tobacco-product-applications
5. U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs